Histidine
Histidine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target pituitary adenylate cyclase-activating polypeptide type I receptor, solute carrier family 15 member 4, vasoactive intestinal polypeptide receptor 2, secretin receptor, carbonic anhydrase 7, carbonic anhydrase 5A, mitochondrial, carbonic anhydrase 1, sodium-coupled neutral amino acid transporter 5, vasoactive intestinal polypeptide receptor 1, carbonic anhydrase 14, and solute carrier family 15 member 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2025-11-02 |
| aminosyn-pf | New Drug Application | 2025-10-17 |
| clinimix | New Drug Application | 2021-04-13 |
| clinimix e | New Drug Application | 2021-04-13 |
| clinisol | ANDA | 2018-06-01 |
| kabiven | New Drug Application | 2025-09-11 |
| novoseven | Biologic Licensing Application | 2010-08-06 |
| perikabiven | New Drug Application | 2025-09-15 |
| plenamine | ANDA | 2026-05-08 |
| premasol - sulfite-free (amino acid) | ANDA | 2022-08-04 |
Show 6 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
139 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 5 | 7 | 6 | 1 | — | 16 |
| Coronary artery disease | D003324 | — | I25.1 | — | 2 | 1 | 1 | — | 4 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | 1 | 2 | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 1 | 1 | — | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | 1 | 1 | 1 | 3 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | 1 | — | 2 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | 1 | — | 2 |
| Dermatitis | D003872 | — | L30.9 | — | — | — | 1 | 1 | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | 1 | 2 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | — | 1 | — | 1 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 vaccines | D000086663 | — | — | 3 | — | 2 | — | — | 5 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | 2 | 3 |
| Neoplasms | D009369 | — | C80 | 2 | — | 1 | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | — | 2 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | 1 | 2 |
| Virus diseases | D014777 | — | B34 | 1 | — | 1 | — | — | 2 |
| Rabies | D011818 | — | A82 | — | — | 2 | — | — | 2 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 1 | 1 | — | — | 2 |
| Menkes kinky hair syndrome | D007706 | — | — | 1 | 1 | 1 | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | 1 | — | — | 2 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 4 | — | — | 1 | 5 |
| Malaria | D008288 | EFO_0001068 | B54 | 1 | 1 | — | — | 4 | 5 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 1 | — | — | — | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 2 | — | — | — | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 2 | — | — | — | 3 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 1 | — | — | 2 | 3 |
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 2 |
| Fatigue | D005221 | — | R53.83 | 1 | 1 | — | — | — | 2 |
| Sclerosis | D012598 | — | — | 1 | 1 | — | — | — | 2 |
Show 47 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | 1 | 5 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | — | 1 | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Herpes genitalis | D006558 | EFO_0007282 | A60 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Chronic pain | D059350 | — | — | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 3 | 3 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 2 | 2 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 2 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 2 | 2 |
| Abdominal obesity | D056128 | — | — | — | — | — | — | 2 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 2 | 2 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
| Intestinal diseases | D007410 | — | K63.9 | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Histidine |
| INN | histidine |
| Description | L-histidine is the L-enantiomer of the amino acid histidine. It has a role as a nutraceutical, a micronutrient, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a human metabolite, an algal metabolite and a mouse metabolite. It is a proteinogenic amino acid, a histidine and a L-alpha-amino acid. It is a conjugate base of a L-histidinium(1+). It is a conjugate acid of a L-histidinate(1-). It is an enantiomer of a D-histidine. It is a tautomer of a L-histidine zwitterion. |
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1c[nH]cn1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 71-00-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL17962 |
| ChEBI ID | 15971 |
| PubChem CID | 6274 |
| DrugBank | DB00117 |
| UNII ID | 4QD397987E (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Novoseven – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 131,028 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aminosyn ii, Novoseven, Trepoxicam, Trepoxicam-7.5
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
436 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use